Pfizer Inc. (NYSE:PFE), proposed buying AstraZeneca Plcfor about 58.8 billion pounds ($98.7 billion) and is still interested in a deal after the U.K. company spurned the offer. Pfizer Inc. (NYSE:PFE), shares after opening at $30.73 moved to $30.80 on last trade day and at the end of the day closed at $30.75. Company price to sales ratio in past twelve months was calculated as 3.81 and price to cash ratio as 6.07. Pfizer Inc. (NYSE:PFE), showed a positive weekly performance of 1.65%.
AbbVie Inc (NYSE:ABBV), a $79.5 billion drug company, has submitted to the U.S. Food and Drug Administration an approval request for its all-oral, but promising treatment for hepatitis C. The company’s application banks on strong study results obtained with the drug. The company expects FDA to hand approval for the drug this year to allow commercialization. AbbVie Inc (NYSE:ABBV), shares fell 0.36% in last trading session and ended the day on $49.14. AbbVie Inc (NYSE:ABBV), return on equity ratio is recorded as 113.20% and its return on assets is 14.70%. AbbVie Inc (NYSE:ABBV), yearly performance is 15.03%.
Shares of Merck & Co., Inc. (NYSE:MRK), have earned an average rating of “Buy” from the sixteen analysts that are currently covering the stock,American Banking News reports. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $58.20. Merck & Co., Inc. (NYSE:MRK), shares moved down 0.50% in last trading session and was closed at $57.24, while trading in range of $ 57.02 – 57.68. Merck & Co., Inc. (NYSE:MRK), year to date (YTD) performance is 15.26%.
Johnson & Johnson (NYSE:JNJ), announced results for the first quarter of its fiscal year 2014 (1QFY14; ended March 29, 2014), beating analysts’ estimates for earnings and revenues. The pharmaceutical industry bellweather also upgraded its earnings guidance for 2014. The stock price of the company was up 1.5% following the announcement of the results. Johnson & Johnson (NYSE:JNJ), weekly performance is 0.84%. On last trading day company shares ended up $99.79. Johnson & Johnson (NYSE:JNJ), distance from 50-day simple moving average (SMA50) is 4.87%. Analysts mean target Price for the company is $104.55.